Investigational Drug Protocol Navigator & Expanded Access Simulator

Scenario Presets

Clinical Indication Archetype Starting Dose (mg) 10 mg Dose Escalation Factor 1.5x DLT Threshold Limit 33% Participant Motivation & Profile

Expanded Access Pathway:

Single-Patient Emergency IND (FDA 21 CFR 312.310)

Bioethics Mandate:

IRB full-board review mandatory with validated therapeutic misconception screening.

Trial Phase

Phase I Dosing Escalation

Projected MTD (mg)

33.75 mg

Toxicity Prob @ MTD

18.0%

Active Cohorts

4 Evaluated